SPRY

ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Donn Casale - CEO, President & Director Meg Smith Kathleen Scott - Chief Financial Officer Conference Call Participants Monique Allaire - Thrust Strategic Communications Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Frank Wang Zhong - Leerink Partners LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, and welcome to ARS Pharma's Third Quarter 2026 Earnings Conference Call.

ARS Pharmaceuticals NASDAQ: SPRY reported $33.4 million in third-quarter U.S. net product revenue from its needle-free epinephrine treatment neffy and reaffirmed its goal of reaching cash flow breakeven by the end of 2027.

ARS Pharmaceuticals is rated Buy, with current market pricing disconnected from fundamental pipeline value despite commercial setbacks. neffy, the flagship intranasal epinephrine spray, faces slow adoption and insurance hurdles but shows potential for significant market share and revenue. Management pivots to a leaner, targeted prescriber approach, aiming for late-2027 cash-flow breakeven while addressing heavy cash burn and term debt.

ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to review its third quarter 2026 financial results.

NEW YORK--(BUSINESS WIRE)---- $SPRY #ARS--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. ("“ARS Pharmaceuticals” or the “Company”) (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California an.

NEW YORK, Oct. 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

LOS ANGELES, Oct. 5, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

New York, New York--(Newsfile Corp. - October 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

New York, New York--(Newsfile Corp. - October 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us.